Loading quotes...
Forecast
The analysts' average price target is €28.62 (+2.58%). The median is €28.56 (+2.37%).
| Buy |
6 |
| Hold |
15 |
| Sell |
2 |
News Go to news feed
Smith+Nephew Q1 2026: innovation drives growth despite regional divergences
Smith+Nephew reported revenue of USD 1,501 million for Q1 2026 and organic growth of 3.1%, with favorable currency effects lifting reported growth to 6.6%. Strong performance in Sports Medicine & ENT (+6.7%) and in emerging markets (+10.5%) contrasted with a weak orthopaedics portfolio (+0.8%) and only moderate growth in the US (+2.1%). New products contributed more than half of the growth, the company confirmed its full-year guidance and announced a USD 500 million share buyback program. » More on de.investing.com
Smith & Nephew CEO Deepak Nath to become independent non-executive director at Reckitt Benckiser
Smith & Nephew announced that CEO Deepak Nath will be appointed as an independent non-executive director at Reckitt Benckiser, effective 1 April 2026. Nath will remain in his role as CEO of Smith & Nephew. The announcement was made as part of a required disclosure under UK listing rules and is based on a notice recently filed with the SEC. » More on de.investing.com
Moody’s affirms Baa2 for Smith & Nephew and raises outlook to positive
Moody’s has affirmed Smith & Nephew’s long-term issuer rating at Baa2 and changed the outlook from “stable” to “positive.” The agency cites solid organic revenue and margin growth, improved free cash flow generation and conservative financial policy with a target net leverage of around 2x. Moody’s expects adjusted gross leverage of about 2.3x for 2025 and 2.2x for 2026, and free cash flow after dividends of roughly USD 400m and USD 500m, respectively. An upgrade is possible if the company achieves sustainable organic revenue and EBITDA growth, continued margin expansion, strong free cash flow generation and a gross leverage sustainably below 2.5x. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 2.72B | - |
| Gross profit | 1.93B | - |
| Net profit | 265.94M | - |
| EBITDA | 656.52M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €12.14B |
Number of shares | 434.54M |
52-week high/low | €33.26 - €23.42 |
Dividend yield | 2.49% |
Dividends TTM | €0.69 |
Beta | 0.69 |
P/E ratio | 20.40 |
PEG ratio | 0.61 |
P/B ratio | 2.53 |
P/S ratio | 2.03 |
Company profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
| Name | Smith & Nephew ADR |
| CEO | Deepak S. Nath |
| Headquarters | Watford,
hrt United Kingdom |
| Website | |
| Sector | Industrials |
| Industry | Commercial Services & Supplies |
| IPO | 12/08/2017 |
| Employees | 18,362 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | SNN |
Frankfurt | NPWA.F |
Düsseldorf | NPWA.DU |